Agios Pharmaceuticals (AGIO) closed the last trading session at $32.80, gaining 10.4% over the past four weeks, but there ...

AGIO stock results show that Agios Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for ...

Cantor Fitzgerald raised the price target for the Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock to “an Overweight”. The rating was released on February 08, 2024, according to finviz. The research ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.47 per share a year ago.

Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary Vandana ...

Investors in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) had a good week, as its shares rose 9.7% to close at US$34.54 ...

NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end-of-month settlement dates. It is then ...